Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Hypothalamic 5-HT1B-receptor changes in anorectic tumor bearing rats.

Authors: Makarenko, IG  Meguid, MM  Gatto, L  Goncalves, CG  Ramos, EJ  Chen, C  Ugrumov, MV 
Citation: Makarenko IG, etal., Neurosci Lett. 2005 Mar 11;376(2):71-5. Epub 2004 Dec 8.
Pubmed: (View Article at PubMed) PMID:15698923
DOI: Full-text: DOI:10.1016/j.neulet.2004.11.026

Serotonin (5-HT) is an anorectic monoamine and its regulatory effects on feeding are mediated primarily via 5-HT1B-receptors localized in the hypothalamic nuclei, which, apart from the brain stem, are among the most crucial areas of food intake regulation. The distribution of 5-HT1B-receptors in the hypothalamic nuclei was studied in tumor-bearing (TB) rats at the onset of anorexia and in sham-operated control rats, using the peroxidase-anti-peroxidase immunocytochemical method and specific polyclonal antiserum. Semiquantitative image analysis of 5-HT1B-receptor immunostaining was performed on high-resolution digital photomicrographs using the NIH Scion Image analysis program and the data were compared using Student's t-test. Immunostaining detected 5-HT1B-receptor proteins in the same hypothalamic structures in the Controls as in the TB rats. Qualitative and semiquantitative analysis revealed a significant increase in 5-HT1B-receptor expression in the magnocellular neurons of paraventricular and supraoptic hypothalamic nuclei in TB rats versus Controls. In contrast, changes were not significant in the parvocellular portion of paraventricular nucleus or in the lateral hypothalamus including perifornical region. These findings emphasize serotonin's influence on the magnocellular hypothalamic nuclei during developing of cancer anorexia, which is associated with a decrease in food intake.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 1626473
Created: 2007-08-09
Species: All species
Last Modified: 2007-08-09
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.